Novan Inc. (NOVN) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Contrasting side by side

We will be contrasting the differences between Novan Inc. (NASDAQ:NOVN) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) as far as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novan Inc. 2 0.00 18.09M -0.56 0.00
Arena Pharmaceuticals Inc. 48 -0.28 50.01M 12.15 5.16

Table 1 showcases the top-line revenue, earnings per share and valuation of Novan Inc. and Arena Pharmaceuticals Inc.


Table 2 has Novan Inc. and Arena Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Novan Inc. 826,744,664.32% 0% -49.7%
Arena Pharmaceuticals Inc. 104,405,010.44% 84.7% 76.3%

Analyst Recommendations

Novan Inc. and Arena Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Novan Inc. 0 0 0 0.00
Arena Pharmaceuticals Inc. 0 2 0 2.00

Meanwhile, Arena Pharmaceuticals Inc.’s consensus target price is $54.5, while its potential upside is 16.03%.

Insider and Institutional Ownership

The shares of both Novan Inc. and Arena Pharmaceuticals Inc. are owned by institutional investors at 5.5% and 86.3% respectively. 2.4% are Novan Inc.’s share held by insiders. Insiders Comparatively, held 0.2% of Arena Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Novan Inc. 1.15% -2.59% 119.17% 97.74% -2.59% 216.87%
Arena Pharmaceuticals Inc. -1.03% 5.03% 41.87% 39.44% 63.57% 60.92%

For the past year Novan Inc. has stronger performance than Arena Pharmaceuticals Inc.


On 8 of the 12 factors Arena Pharmaceuticals Inc. beats Novan Inc.

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The companyÂ’s product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. The company has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The companyÂ’s proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.